COVAX only (1st and 2nd dose)

BIOLOGICAL2 trials

Sponsors

China National Biotec Group Company Limited

Conditions

COVID-19 PneumoniaCovid19Influenza, HumanPneumonia, Pneumococcal

Phase 4

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

CompletedNCT04790851

China National Biotec Group Company LimitedCovid19, Influenza, Human, Pneumonia, Pneumococcal

Start: 2021-03-10End: 2021-09-05Updated: 2021-10-20

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

China National Biotec Group Company LimitedCOVID-19 Pneumonia, Influenza, Human, Pneumonia, Pneumococcal

Start: 2021-05-06End: 2021-12-31Updated: 2021-10-15

Related Papers

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.

2022-07-2921 citations